
    
      The study objective is to investigate the efficacy and safety of p53 combined with
      chemotherapy (cisplatin and paclitaxel) in treatment of recurrent Ovarian Epithelial Cancer,
      Fallopian Tube Cancer, and Primary Peritoneal Cancer.

      study design: open-labeled, active controlled, randomized, phase 2 treatments: experiment
      group will consist of intraperitoneal p53 (2 x 10^12 viral particles) plus cisplatin 150
      mg/m^2, and Paclitaxel 175 mg/m^2 IV over 3 h on day 1; every 21 d for 6 cycles.

      study end points: response rate, progression-free survival, overall survival and Karnofsky
      scoreï¼ˆKPS).
    
  